Northwest Biotherapeutics Profit Margin

Northwest Biotherapeutics (NWBO) currently reports a profit margin of -3047.56% as of March 2026. That compares with -5784.52% in the prior-year period — up 47.3% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Northwest Biotherapeutics's profit margin history and peer comparisons.

Northwest Biotherapeutics's profit margin increased from -5784.52% to -3047.56% — a 47.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Northwest Biotherapeutics's profit margin of -3047.56% is lower than the Healthcare sector average of 14.34%. That is roughly 21345.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Northwest Biotherapeutics's current -3047.56% should be judged against Healthcare norms (sector average: 14.34%) and against NWBO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3047.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Northwest Biotherapeutics, and consider following NWBO for alerts when major investors trade the stock.